Tag: launch

MONTVILLE, N.J., July 25, 2025 (GLOBE NEWSWIRE) -- Rate, a leading fintech company, proudly announces the addition of Brian Bloete, a decorated U.S. Marine Corps veteran and top-producing loan officer, to its team in Montville, NJ. Bloete joins Rate as part of the company’s continued commitment to attracting elite originators who prioritize service, integrity, and performance.

VYJUVEK approved for the treatment of DEB from birth with flexible administration options including home dosing and the option for administration by the patient or their family

MADRID, 25 July 2025 – Neinor Homes (“Neinor”) (HOME SM), the leading residential platform in Spain, has announced its results for the first half of 2025, confirming the continued growth of its Asset Management business, solid operating margins, and a record commercialization activity. The period also marks an acceleration in the Company’s investment strategy with the launch of a voluntary tender offer for 100% of Aedas Homes’ capital.

With a production budget that surpasses Squid Game Season 1, Trigger emerges as Netflix’s next high-stakes Korean mega-production

SINGAPORE, July 25, 2025 (GLOBE NEWSWIRE) -- Orangekloud Technology Inc. (Nasdaq: ORKT) (“Orangekloud” or “the Company”), a Singapore-based technology company offering the eMOBIQ®️ No-Code platform for development of mobile applications, today announced the official launch of eMOBIQ®️ AI, an AI-driven no-code development platform enabling users to build, customize, and deploy enterprise-grade applications using natural language alone.

Stage 2 Will Introduce Price Increase and APY Adjustment as Project Prepares for Solana Deployment and AI-Driven Governance Rollout

NEW YORK and MAINZ, GERMANY, July 25, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the companies’ LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY^® LP.8.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the EMA’s Emergency Task Force (ETF) to update COVID-19 vaccines to target the LP.8.1 variant for the 2025-2026 season. The ETF stated that “targeting LP.8.1 will help maintain the effectiveness of the vaccines as SARS-CoV-2 continues to evolve.”²